India-based Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines. The company enjoys a strong position in the generics market.
Currently, Dr. Reddy’s has a Zacks Rank #4 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Dr. Reddy’s third quarter fiscal 2019 earnings of 41 cents per share, compared with 29 cents reported in the year ago quarter.
Revenues Beat: Dr. Reddy’s posted revenues of $553 million an increase of 1.1% year over year.
Key Statistics:Revenues from Global Gereics segment increased 4% year over year, and from the Pharmaceutical Services and Active Ingredients (PSAI) segment increased 9% year over year. Sales from the Proprietary Products segment declined 66% from the year ago quarter.
Pre-Market Trading: Shares increased 2.6% in pre-market trading.
Check back later for our full write up on this RDY earnings report later!
Dr. Reddy's Laboratories Ltd Price and EPS Surprise
Dr. Reddy's Laboratories Ltd Price and EPS Surprise | Dr. Reddy's Laboratories Ltd Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Dr. Reddy's Laboratories Ltd (RDY): Free Stock Analysis Report
Original post
Zacks Investment Research